Form 4: uniQure Director Rachelle Jacques Boosts Equity Stake Through Incentive Grants

uniQure N.V. Director Rachelle Suzanne Jacques was granted 7,970 restricted share units and 15,630 stock options on June 11, 2025, as part of the company's incentive plan.

Summary

• Rachelle Suzanne Jacques, a Director of uniQure N.V. (QURE), acquired 7,970 Ordinary Shares through restricted share units (RSUs) on June 11, 2025.
• These RSUs were granted under the Issuer's 2014 Share Incentive Plan, as amended and restated, and vest 100% on the first anniversary of the grant date (June 11, 2026), subject to her continued relationship with the company.
• Additionally, Ms. Jacques was granted 15,630 stock options on June 11, 2025, with an exercise price of $16.22 per share.
• These stock options also vest 100% on the first anniversary of the grant date (June 11, 2026) and expire on June 11, 2035, contingent on her continued relationship with uniQure.
• Following these transactions, Ms. Jacques beneficially owns 30,458 Ordinary Shares directly and 15,630 stock options directly.

Sentiment

Score: 7

Explanation: The document reports routine equity grants to a director, which is generally a positive sign of alignment between management and shareholder interests, but does not contain new financial performance data or significant strategic shifts.

Positives

• A director receiving equity grants (RSUs and stock options) aligns their interests with shareholders, indicating confidence in the company's future performance and long-term value creation.
• The grants are part of an established incentive plan, which is a common and effective practice to attract, retain, and motivate key talent within the company.

Risks

• The vesting of both the restricted share units and stock options is contingent upon the reporting person's continued relationship with uniQure N.V., meaning the benefits are not guaranteed if her association with the company ceases before the vesting date.
• The ultimate value realized from the stock options is dependent on uniQure N.V.'s share price exceeding the exercise price of $16.22 per share at the time of exercise.

Future Outlook

The grants of restricted share units and stock options with future vesting dates indicate an expectation of continued employment or board service for the reporting person and align her incentives with the long-term performance and strategic goals of uniQure N.V.

Industry Context

Equity grants to directors and executives are standard practice in the biotechnology and pharmaceutical industries to incentivize long-term commitment and performance, especially given the long development cycles and high-risk nature of drug development. Such grants aim to align the interests of key personnel with shareholder value creation and are a common component of competitive compensation packages.

Comparison to Industry Standards

• Equity compensation packages, including restricted share units and stock options, are a common and competitive practice within the biotechnology and pharmaceutical sectors to attract and retain high-caliber talent.
• While specific comparable companies or projects are not detailed in this filing, the structure of these grants is consistent with typical executive and director compensation strategies seen across the industry, such as those at companies like BioNTech, Moderna, or Regeneron, which frequently use equity to reward and retain leadership.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term shareholder value and demonstrating confidence from an insider.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for broader employee incentive programs and reflect the company's approach to talent retention.

Next Steps

• The restricted share units and stock options are scheduled to vest on June 11, 2026, subject to the director's continued relationship with uniQure N.V.
• The stock options will expire on June 11, 2035, if not exercised.

Key Dates

Recommendation

Keywords

uniQure N.V., QURE, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Share Units, Stock Options, Equity Compensation, Director Compensation, Biotechnology, Pharmaceuticals